Ranolazine as a promising treatment option for atrial fibrillation: Electrophysiologic mechanisms, experimental evidence, and clinical implications

PACE - Pacing and Clinical Electrophysiology

Volumn 37, Issue 10, 2014, Pages 1412-1420

  Fragakis, Nikolaos ^a   Koskinas, Konstantinos C ^a   Vassilikos, Vassilios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

atrial fibrillation; clinical trials; pharmacology; ranolazine

Indexed keywords

ANTIARRHYTHMIC AGENT; ION CHANNEL; RANOLAZINE; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE;

ACUTE CORONARY SYNDROME; CARDIOVERSION; CLINICAL STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EXPERIMENTAL MODEL; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REVASCULARIZATION; HUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SINUS RHYTHM; SODIUM CURRENT; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ELECTROPHYSIOLOGY;

ACETANILIDES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; ELECTROPHYSIOLOGICAL PHENOMENA; HUMANS; PIPERAZINES;

EID: 84907986717     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12486     Document Type: Review

References (52)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE,. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. J Am Med Assoc 2001; 285: 2370-2375.
2. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr., Cigarroa JE, Conti JB, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014 (in press;doi: 10.1016/j.jacc.2014.03.022).
3. Fragakis N, Katritsis DG,. Surgical treatment for atrial fibrillation: Where do we stand ? Hellenic J Cardiol 2012; 53: 210-216.
4. Burashnikov A, Antzelevitch C,. Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther 2011; 132: 300-313.
5. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C,. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007; 116: 1449-1457.
6. Chaitman BR,. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006; 113: 2462-2472.
7. Anderson JR, Nawarskas JJ,. Ranolazine: A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev 2005; 13: 202-210.
8. Undrovinas AI, Fleidervish IA, Makielski JC,. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992; 71: 1231-1241.
9. Ju YK, Saint DA, Gage PW,. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 1996; 497: 337-347.
10. Huang B, El-Sherif T, Gidh-Jain M, Qin D, El-Sherif N,. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol 2001; 12: 218-225.
11. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI,. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: Implications for repolarization variability. Eur J Heart Fail 2007; 9: 219-227.
12. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S,. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000; 101: 2631-2638.
13. 2+ exchange. Circ Res 2002; 90: 988-995.
14. Allessie M, Ausma J, Schotten U,. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246.
15. Wit AL, Boyden PA,. Triggered activity and atrial fibrillation. Heart Rhythm 2007; 4 (3 Suppl): S17-S23.
16. Nattel S, Dobrev D,. The multidimensional role of calcium in atrial fibrillation pathophysiology: Mechanistic insights and therapeutic opportunities. Eur Heart J 2012; 33: 1870-1877.
17. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kühlkamp V,. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44: 121-131.
18. Wettwer E, Christ T, Endig S, Rozmaritsa N, Matschke K, Lynch JJ, Pourrier M, et al. The new antiarrhythmic drug vernakalant: Ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res 2013; 98: 145-154.
19. + currents in atrial fibrillation new drug target or just an epiphenomenon ? J Am Coll Cardiol 2010; 55: 2343-2345.
20. + currents in atrial fibrillation: Effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010; 55: 2330-2342.
21. Verheule S, Wilson E, Everett T 4th, Shanbhag S, Golden C, Olgin J,. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003; 107: 2615-2622.
22. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kühlkamp V,. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999; 44: 121-131.
23. + current in a chronic dog model of atrial fibrillation. Circ Res 1997; 81: 1045-1052.
24. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, et al. Electrophysiologic effects of ranolazine: A novel anti-anginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-910.
25. Guo D, Lian J, Liu T, Cox R, Margulies KB, Kowey PR, Yan GX,. Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT prolonging agents. Heart Rhythm 2011; 8: 762-769.
26. Burashnikov A, Antzelevitch C,. Atrial-selective sodium channel blockers: Do they exist ? J Cardiovasc Pharmacol 2008; 52: 121-128.
27. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L,. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011; 8: 1281-1290.
28. + current. J Cardiovasc Pharmacol 2008; 51: 581-589.
29. Starmer CF, Grant AO, Strauss HC,. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anaesthetics. Biophys J 1984; 46: 15-27.
30. + channel isoforms by ranolazine. Mol Pharmacol 2008; 73: 940-948.
31. + current by ranolazine. Heart Rhythm 2009; 6: 1625-1631.
32. Aidonidis I, Doulas K, Hatziefthimiou A, Tagarakis G, Simopoulos V, Rizos I, Tsilimingas N, et al. Ranolazine induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther 2013; 18: 94-101.
33. Wu L, Shryock JC, Song Y, Belardinelli L,. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004; 310: 599-605.
34. Sicouri S, Glass A, Belardinelli L, Antzelevitch C,. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008; 5: 1019-1026.
35. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C,. Synergistic effect of the combination of dronedarone and ranolazine to suppress atrial fibrillation. J Am Coll Cardiol 2010; 56: 1216-1224.
36. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C,. Synergistic electrophysiologicand antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol 2010; 3: 88-95.
37. Frommeyer G, Milberg P, Uphaus T, Kaiser D, Kaese S, Breithardt G, Eckardt L,. Antiarrhythmic effect of ranolazine in combination with class-III drugs in an experimental whole heart model of atrial fibrillation. Cardiovasc Ther 2013; 31: e63-e71.
38. Kodama I, Kamiya K, Toyama J,. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999; 84: 20R-28R.
39. Verrier RL, Sobrado MF, Pagotto VP, Kanas AF, Machado AD, Varone BB, Sobrado LF, et al. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart Rhythm 2013; 10: 121-127.
40. Frommeyer G, Kaiser D, Uphaus T, Kaese S, Osada N, Rajamani S, Belardinelli L, et al. Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm 2012; 9: 2051-2058.
41. Frommeyer G, Schmidt M, Clauß C, Kaese S, Stypmann J, Pott C, Eckardt L, et al. Further insights into the underlying electrophysiologic mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur J Heart Fail 2012; 14: 1322-1331.
42. Milberg P, Frommeyer G, Ghezelbash S, Rajamani S, Osada N, Razvan R, Belardinelli L, et al. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: Prolongation of interatrial conduction time and increase in postrepolarization refractoriness. Europace 2013; 15: 761-769.
43. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-1652.
44. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F,. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008; 8: 175-181.
45. Murdock DK, Kersten M, Kaliebe J, Larrain G,. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009; 9: 260-267.
46. Miles RH, Passman R, Murdock DK,. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2011; 108: 673-676.
47. Murdock DK, Kaliebe J, Larrain G,. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: A case series. Pacing Clin Electrophysiol 2012; 35: 302-307.
48. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P,. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol 2012; 110: 673-677.
49. Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V,. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014; 16: 973-979.
50. Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K, Skoularingis I, et al. Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. Angiology 2013; 65: 294-297.
51. A study to evaluate the effect of ranolazine and dronedarone when given alone and in combination in patients with paroxysmal atrial fibrillation (HARMONY). Available at: http://clinicaltrials.gov/ct2/show/NCT01522651 (accessed June 28, 2014).
52. Kowey PR, Reiffel JA, Camm AJ, Zareba W, Prokopczuk EK, Zeng D, Belardinelli L,. The effect of the combination of ranolazine and low dose dronedarone on atrial fibrillation burden in patients with paroxysmal atrial fibrillation (HARMONY Trial). Abstract presented at the Heart Rhythm Society Scientific Sessions 2014.